[Skip to Navigation]
Sign In
November 25, 2020

Ibrutinib’s Cardiotoxicity—An Opportunity for Postmarketing Regulation

Author Affiliations
  • 1Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois
  • 2Value in Cancer Care Consortium, Ann Arbor, Michigan
  • 3Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, Tennessee
JAMA Oncol. 2021;7(2):177-178. doi:10.1001/jamaoncol.2020.5742
Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words